Clinical Trials Logo

Cancer of Head and Neck clinical trials

View clinical trials related to Cancer of Head and Neck.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05061316 Active, not recruiting - Clinical trials for Cancer of Head and Neck

The Gut Microbiome as an Indicator of Readiness for Head & Neck Cancer Surgery

Start date: March 11, 2022
Phase: N/A
Study type: Interventional

The purpose of this study is to understand how a pre-operative nutritional intervention alters the gut microbiome and improves outcomes after major head and neck cancer surgery.

NCT ID: NCT04617678 Active, not recruiting - Clinical trials for Cancer of Head and Neck

A Comprehensive Approach to Head and Neck Cancer Prehabilitation

Start date: October 21, 2021
Phase: N/A
Study type: Interventional

Head and neck cancer accounts for 3% of malignancies in the United States. However, the diagnosis and treatment for head and neck cancer is considered to be debilitating. Not because of its morbidity, but due to the extremely rigorous treatment course which has a profound impact on patients physical, social, and emotional functioning. Disfigurement and sensorimotor deficits further compound this impact. Head and neck cancer patients contend with treatments that can significantly affect their quality of life. Treatment regularly results in decreased functional capacity and decreased quality of life. Physical impairments are manifested through, but not limited to, disfigurement, deconditioning, communication issues, "swallowing, speech, breathing, and cancer-related fatigue". Premorbid factors such as preexisting anxiety and depression, chemical dependency, financial barriers, and lack of social support system are unique obstacles to the head and neck cancer population impacting treatment and outcomes. Due to these factors, patients experience higher rates of anxiety and depression, psychological distress, and fear of cancer recurrence. In fact, "compared with other survivors of cancer, head and neck cancer survivors are almost 2 times more likely to die from suicide". In view of the aforementioned research, Roger Maris Cancer Center's head and neck cancer will implement a prehabilitation program that evaluates each patient using standardized screening tools and provide personalized education and interventions. This project evaluates a more comprehensive and proactive multidisciplinary approach to improve treatment and outcomes in head and neck cancer patients.

NCT ID: NCT04356170 Active, not recruiting - Clinical trials for Cancer of Head and Neck

Trial Evaluating Adapted Chemotherapy in Patients With Squamous Carcinoma

TPFmORL
Start date: February 4, 2021
Phase: Phase 2
Study type: Interventional

The objective of this study is to evaluate the efficacity of the combination of cisplatin-5-FU and docetaxel in adapted doses in term of response to treatment without toxicity .

NCT ID: NCT03760471 Active, not recruiting - Clinical trials for Cancer of Head and Neck

Palliative and Oncology Care Intervention: Symptom COACH

Start date: November 7, 2018
Phase: N/A
Study type: Interventional

The investigators propose to conduct the first pilot trial of a collaborative palliative and oncology care intervention for HNC patients receiving CRT to assess the feasibility and acceptability of the intervention. The intervention will incorporate weekly palliative care visits into standard oncology care targeting coping, mood, and symptom management.

NCT ID: NCT02573493 Active, not recruiting - Clinical trials for Head and Neck Cancer

Nab-Paclitaxel and Cisplatin or Nab-paclitaxel as Induction Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC)

APA
Start date: April 13, 2016
Phase: Phase 2
Study type: Interventional

In this trial, the objectives are to determine the efficacy and toxicity of induction chemotherapy (IC) with nab-paclitaxel + cisplatin (Arm 1: AP) and with nab-paclitaxel (Arm 2: A) alone in patients with HNSCC, and to compare these data to nab-paclitaxel, cisplatin, and 5-FU (APF). The investigators also hypothesize that the high anti-tumor efficacy of nab-paclitaxel in HNSCC is due to the upregulation of macropinocytosis, a result of the frequent presence of Ras and PI3K (and epidermal growth factor receptor -EGFR) activation in this cancer. Amendment to Add Arm 3: In this amendment, the investigators retain the AP + concurrent chemoradiation therapy (CRT) backbone but de-escalate the dose of radiation therapy (RT) from 70 Gy to 42 Gy. The investigators also plan to administer one dose (vs three) of cisplatin during RT. This novel treatment approach will be evaluated in patients with HPV-related oropharyngeal squamous cell carcinoma (OPSCC) (Arm 3), a sub-group with a very favorable prognosis.

NCT ID: NCT02296684 Active, not recruiting - Clinical trials for Head and Neck Cancer

Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma

Start date: March 25, 2015
Phase: Phase 2
Study type: Interventional

The goal of this trial is to test the ability of MK-3475 (pembrolizumab) to improve locoregional recurrence and distant metastatic rates in high-risk patients with locally advanced head and neck squamous cell carcinomas (HNSCCs) that are treated with current standard of care surgical approaches.

NCT ID: NCT01860430 Active, not recruiting - Clinical trials for Cancer of Head and Neck

A Phase Ib Trial of Concurrent Cetuximab (ERBITUX®) and Intensity Modulated Radiotherapy (IMRT) With Ipilimumab (YERVOY®) in Locally Advanced Head and Neck Cancer

Start date: April 2013
Phase: Phase 1
Study type: Interventional

This clinical trial is aimed to establish a recommended starting dose of ipilimumab for a future efficacy trial when used in combination with intensity modulated radiation therapy (IMRT) and cetuximab.